AstraZeneca PLC/ GB0009895292 /
2024-08-23 5:29:57 PM | Chg. +87.00 | Volume | Bid5:30:00 PM | Ask5:30:00 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
13,083.00GBX | +0.67% | 249,884 Turnover(GBP): 32.74 mill. |
-Bid Size: - | -Ask Size: - | 201.35 bill.GBP | - | - |
GlobeNewswire
08-12
Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune...
GlobeNewswire
08-08
Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets...
GlobeNewswire
06-26
As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Co...
GlobeNewswire
06-20
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Gr...
GlobeNewswire
06-18
Mika Health Collaborates with AstraZeneca and Daiichi Sankyo to Deliver AI-Enabled Mobile Support to...
GlobeNewswire
06-18
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire
06-13
Rheumatologists' Aggressive Approach to SLE Treatment Targets Specific Patient Types with Biologics
GlobeNewswire
05-08
Annual NMDP Gala in New York Raises More Than $560,000, Enabling More Patients to Receive Life-Savin...
GlobeNewswire
05-08
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Bi...
GlobeNewswire
05-06
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
GlobeNewswire
04-01
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AdTheorent ...
GlobeNewswire
03-28
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Pati...